Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Boehringer Ingelheim
Mallinckrodt
McKesson
Colorcon

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022257

See Plans and Pricing

« Back to Dashboard

NDA 022257 describes VALCYTE, which is a drug marketed by Hoffmann La Roche and is included in two NDAs. It is available from one supplier. There are two patents protecting this drug and two Paragraph IV challenges. Additional details are available on the VALCYTE profile page.

The generic ingredient in VALCYTE is valganciclovir hydrochloride. There are seventeen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the valganciclovir hydrochloride profile page.
Summary for 022257
Tradename:VALCYTE
Applicant:Hoffmann La Roche
Ingredient:valganciclovir hydrochloride
Patents:2
Formulation / Manufacturing:see details
Pharmacology for NDA: 022257
Mechanism of ActionDNA Polymerase Inhibitors
Suppliers and Packaging for NDA: 022257
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VALCYTE valganciclovir hydrochloride FOR SOLUTION;ORAL 022257 NDA Genentech, Inc. 0004-0039 0004-0039-09 1 BOTTLE, GLASS in 1 CARTON (0004-0039-09) > 100 mL in 1 BOTTLE, GLASS
Paragraph IV (Patent) Challenges for 022257
Tradename Dosage Ingredient NDA Submissiondate
VALCYTE FOR SOLUTION;ORAL valganciclovir hydrochloride 022257 2011-03-21

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:FOR SOLUTION;ORALStrength50MG/ML
Approval Date:Aug 28, 2009TE:ABRLD:Yes
Patent:  Start TrialPatent Expiration:Dec 11, 2027Product Flag?YSubstance Flag?Delist Request?
Patent:  Start TrialPatent Expiration:Dec 11, 2027Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Moodys
Baxter
Mallinckrodt
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.